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1  | INTRODUC TION
Inflammation has evolved to protect the host from acute insults such 
as infection or physical injury. However, chronic inflammation is as‐
sociated with many age‐related diseases such as atherosclerosis, os‐
teoarthritis and cancer. Senescent cells that drive inflammation also 
play pivotal roles in these diseases (Childs et al., 2016; Jeon et al., 
2017; Kang et al., 2011), and naturally accumulate in tissues during 
ageing (Baker et al., 2016). Strikingly, removal of senescent cells can 
prevent the development of disease and also reverse natural fea‐
tures of ageing (Bakeretal., 2016, 2011; Childs et al., 2016; Jeon et 
al., 2017; Kang et al., 2011). Thus, understanding how senescence 
drives inflammation is of critical importance in health, disease and 
ageing.
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Abstract
Interleukin‐1	alpha	 (IL‐1α) is a powerful cytokine that modulates immunity, and re‐
quires	canonical	cleavage	by	calpain	for	full	activity.	Mature	IL‐1α is produced after 
inflammasome	activation	and	during	cell	senescence,	but	the	protease	cleaving	IL‐1α 
in	these	contexts	is	unknown.	We	show	IL‐1α is activated by caspase‐5 or caspase‐11 
cleavage	 at	 a	 conserved	 site.	 Caspase‐5	 drives	 cleaved	 IL‐1α release after human 
macrophage	 inflammasome	 activation,	 while	 IL‐1α secretion from murine mac‐
rophages	only	requires	caspase‐11,	with	IL‐1β release needing caspase‐11 and cas‐
pase‐1.	Importantly,	senescent	human	cells	require	caspase‐5	for	the	IL‐1α‐dependent 
senescence‐associated	secretory	phenotype	(SASP)	in	vitro,	while	senescent	mouse	
hepatocytes	need	caspase‐11	for	the	SASP‐driven	immune	surveillance	of	senescent	
cells	in	vivo.	Together,	we	identify	IL‐1α as a novel substrate of noncanonical inflam‐
matory	caspases	and	finally	provide	a	mechanism	for	how	IL‐1α is activated during 
senescence. Thus, targeting caspase‐5 may reduce inflammation and limit the delete‐
rious	effects	of	accumulated	senescent	cells	during	disease	and	Aging.
K E Y W O R D S
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Senescence is a protective mechanism that induces permanent 
cell cycle arrest to prevent transmission of defects to the next gen‐
eration, particularly to stop malignant transformation. Replicative 
senescence occurs after repeated cell division critically shortens 
telomeres, while induced senescence occurs after oncogene acti‐
vation,	mitochondrial	 deterioration,	 oxidative	 stress	 or	DNA	dam‐
age	(Munoz‐Espin	&	Serrano,	2014).	As	ageing	drives	tumorigenesis	
and telomere shortening, it induces senescence via both pathways. 
Most senescent cells develop altered secretory activities known as 
a	senescence‐associated	secretory	phenotype	(SASP).	The	SASP	re‐
leases	 proinflammatory	 cytokines	 (e.g.,	 IL‐1,	 IL‐6)	 and	 chemokines	
(e.g.,	IL‐8,	GROα),	growth	factors	(e.g.,	G‐CSF,	bFGF),	and	proteases	
(e.g.,	MMPs,	PAI‐1)	 (Coppe	et	 al.,	 2008),	 conferring	diverse	 activi‐
ties. Thus, although cell cycle arrest during senescence limits can‐
cer	 and	 the	 SASP	 instructs	 clearance	 of	 preneoplastic	 cells	 (Kang	
et al., 2011), this is balanced against establishment of a chronic in‐
flammatory microenvironment that can damage tissue, drive disease 
and promote tumorigenesis if senescent cells persist (Grivennikov, 
Greten,	 &	 Karin,	 2010).	 IL‐1α acts in an autocrine/paracrine fash‐
ion	to	drive	the	SASP	(Gardner,	Humphry,	Bennett,	&	Clarke,	2015;	
Orjalo,	 Bhaumik,	Gengler,	 Scott,	&	Campisi,	 2009),	with	 upstream	
expression	controlled	in	part	by	ATM/ATR	liberation	of	GATA4	from	
p62‐directed autophagy (Kang et al., 2015) and/or an mTORC1‐
dependent	 pathway	 (Laberge	 et	 al.,	 2015).	 However,	 how	 IL‐1α is 
cleaved, activated or released during senescence to enable it to drive 
the	SASP	is	unknown.
Interleukin‐1	 (IL‐1)	 is	 an	 ancient	 cytokine	 that	 exerts	 effect	on	
both	 innate	 and	adaptive	 immunities.	 IL‐1α	 and	 IL‐1β are the prin‐
cipal	 ligands	 that	bind	to	 the	type	1	 IL‐1	receptor	 (IL‐1R1),	causing	
recruitment	of	the	IL‐1	receptor	accessory	protein	(IL‐1RAP)	and	sub‐
sequent interaction with the signalling adapter MyD88 (Dinarello, 
2009).	 A	 consequent	 phospho‐signalling	 cascade	 activates	 NF‐κB 
leading to multiple effects on immunity including cytokine secre‐
tion, upregulation of adhesion and/or MHC/costimulatory mole‐
cules, increased vascular permeability, TH17 cell differentiation, 
and effector T‐cell proliferation in the presence of regulatory T cells 
(Sims	&	Smith,	2010).	These	powerful	actions	of	IL‐1	are	countered	
by	a	receptor	antagonist	(IL‐1RA),	a	decoy	receptor	(IL‐1R2),	and	pro‐
duction	of	IL‐1α	and	IL‐1β as pro‐proteins that require cleavage for 
full	biological	activity.	IL‐1α is canonically cleaved by calpain, which 
occurs upon necrosis in some cell types and significantly increases 
activity	 (Burzynski,	 Humphry,	 Bennett,	 &	 Clarke,	 2015;	 Zheng,	
Humphry,	Maguire,	Bennett,	&	Clarke,	2013),	while	IL‐1β is activated 
by caspase‐1 (Black et al., 1988) after inflammasome engagement 
(Martinon,	Burns,	&	Tschopp,	2002).	How	IL‐1α is released without 
necrosis	 is	unknown	and	puzzling	since	IL‐1α release is inhibited in 
Casp1−/− mice	(Kuida	et	al.,	1995;	Li	et	al.,	1995),	even	though	IL‐1α is 
not a caspase‐1 substrate. However, the original Casp1−/− mice have 
an inactivating passenger mutation in Casp11 (Kayagaki et al., 2011), 
suggesting	caspase‐11	might	activate	IL‐1α. Murine caspase‐11 and 
the human orthologues caspase‐4 and caspase‐5 are required for 
noncanonical inflammasome activation in response to intracellular 
LPS	 (icLPS)	 from	 bacterial	 infection	 (Kayagaki	 et	 al.,	 2011;	 Shi	 et	
al.,	2014),	and	control	monocyte	 IL‐1	 release	 (Vigano	et	al.,	2015).	
Direct	binding	of	LPS	to	caspase‐11,	caspase‐4	or	caspase‐5	leads	to	
pyroptosis	and/or	NLRP3	inflammasome	activation,	with	IL‐1β and/
or	 IL‐1α release (Kayagaki et al., 2011; Shi et al., 2014). However, 
whether caspase‐4/5 or caspase‐11 requires caspase‐1 to mediate 
IL‐1α	activation,	if	IL‐1α is only passively released, or if caspase‐4/5 
or	caspase‐11	can	directly	cleave	and	activate	IL‐1α in any of these 
systems is unknown.
We	 show	 that	 IL‐1α is specifically cleaved and activated at a 
conserved site by caspase‐5 and caspase‐11, but not caspase‐4. 
Knockdown of caspase‐5 or expression of a caspase site mutant re‐
duces	release	of	IL‐1α	after	icLPS	stimulation.	IL‐1α cleavage and re‐
lease	from	murine	macrophages	after	icLPS	require	only	caspase‐11,	
while	 IL‐1β needs both caspase‐11 and caspase‐1. Importantly, we 
show caspase‐5 and caspase‐11 are required for senescent cells to 
establish	the	IL‐1α‐dependent	SASP.	Thus,	IL‐1α is a direct substrate 
for inflammatory caspases during noncanonical inflammasome acti‐
vation and senescence.
2  | RESULTS
2.1 | Caspase‐5 cleavage of human IL‐1α at a 
conserved site increases activity
Although	 noncanonical	 inflammasomes	 that	 utilize	 caspase‐4	 and	
caspase‐5	result	in	IL‐1α	and/or	IL‐1β release (Kayagaki et al., 2011; 
Shi	 et	 al.,	 2014),	 their	 role	 in	 cleavage	or	 secretion	 of	 IL‐1α is un‐
known.	Thus,	we	investigated	whether	IL‐1α could be proteolytically 
activated	 by	 these	 caspases.	 Incubation	 of	 recombinant	 pro‐IL‐1α 
with active inflammatory caspases revealed that caspase‐5 cleaved 
IL‐1α to a ~19 kDa fragment, while caspase‐1 or caspase‐4 did not 
(Figure	 1a),	 resulting	 in	 increased	 IL‐1α‐specific cytokine activity 
(Figure	 1b).	 Both	 cleavage	 and	 increased	 IL‐1α activities were de‐
pendent	 on	 caspase‐5	 proteolytic	 activity,	 as	 the	 inhibitor	 LEVD‐
fmk	 reduced	 both	 (Figure	 1c,d).	 Caspases	 require	 Asp	 before	 the	
cleavage	 site,	 and	 thus,	 important	 substrates	 show	Asp	 conserva‐
tion	 between	 species.	 Aligned	 IL‐1α protein sequences revealed a 
conserved	 IAND	tetrapeptide	motif	 (Figure	1e),	a	known	target	of	
granzyme	B	 (Afonina	et	al.,	2011),	with	the	Asp	present	 in	81%	of	
all sequences available (Ensembl). Cleavage at D103 would produce a 
~19 kDa C‐terminal fragment, which is congruent with the size seen 
by	Western	blot	(Figure	1a).	Mutation	of	Asp103	to	Ala	abolished	cas‐
pase‐5	cleavage	of	pro‐IL‐1α	(Figure	1f)	and	thus	prevented	activa‐
tion	(Figure	1g).	This	shows	that	caspase‐5	increases	IL‐1α activity by 
direct processing at a conserved site located adjacent to the calpain 
site	(Figure	1h).
2.2 | Release of cleaved IL‐1α from human cells 
requires caspase‐5
Due	to	the	similar	size	of	calpain‐	and	caspase‐5‐cleaved	IL‐1α, we 
produced a peptide antibody that was reactive to the region between 
the	calpain	and	caspase‐5	sites	(Supporting	information	Figure	S1a)	
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and	 developed	 an	 ELISA	 that	 recognized	 caspase‐5‐cleaved	 IL‐1α, 
but	not	pro‐IL‐1α	or	calpain‐cleaved	IL‐1α	(Figure	2a	and	Supporting	
information	 Figure	 S2b).	We	 also	 established	 an	 IL‐1α	 ELISA	 that	
recognized	total	cleaved	IL‐1α,	but	not	pro‐IL‐1α (Supporting infor‐
mation	Figure	S1c).	To	test	IL‐1α processing and release in cells, we 
expressed	pro‐caspase‐5	and	either	wild‐type	(WT)	or	D103A	mutant	
pro‐IL‐1α	in	HeLa	cells,	and	transfected	LPS	into	the	cytosol	(icLPS)	
to activate the noncanonical inflammasome. D103A	transfected	cells	
released	less	total	cleaved	(Figure	2b)	and	less	non‐calpain‐cleaved	
IL‐1α	(Figure	2c).	Calpain	cleaved	D103A	equivalently	to	WT	pro‐IL‐1α 
(Figure	2d),	showing	the	mutation	only	prevents	noncanonical	pro‐
cessing.	Furthermore,	HeLa	cells	expressing	WT	pro‐IL‐1α produced 
a	19	kDa	 IL‐1α fragment that was absent in D103A	expressing	cells	
after	 icLPS	 (Figure	 2e).	 Primary	 human	 monocyte‐derived	 mac‐
rophages (hMDMs) primed and then noncanonically activated with 
icLPS	 released	 non‐calpain‐cleaved	 IL‐1α	 (Figure	 2f).	 Surprisingly,	
LPS/ATP‐activated	 hMDMs	 also	 produced	 non‐calpain‐cleaved	
IL‐1α	 (Figure	2g),	 suggesting	 caspase‐5	may	also	 cleave	 some	pro‐
IL‐1α after canonical stimulation, likely due to the late activation of 
caspase‐11 by caspase‐1 (Kayagaki et al., 2011). Importantly, knock‐
down	 of	 caspase‐5	 in	 hMDMs	 (Figure	 2h)	 resulted	 in	 decreased	
release	 of	 total	 cleaved	 (Figure	 2i)	 and	 non‐calpain‐cleaved	 IL‐1α 
(Figure	2j)	after	 icLPS	treatment.	This	suggests	that	caspase‐5	can	
directly	process	IL‐1α in cells, which results in increased activity and 
its subsequent release.
2.3 | Release of cleaved IL‐1α from murine 
macrophages requires caspase‐11
Caspase‐11 is the murine orthologue of human caspase‐4 and cas‐
pase‐5,	with	all	directly	binding	icLPS	(Kayagaki	et	al.,	2013;	Shi	et	
al.,	 2014),	 signifying	 functional	 conservation.	 Although	 caspase‐4	
F I G U R E  1  Caspase‐5	cleavage	of	human	IL‐1α	at	a	conserved	site	increases	activity.	(a)	Western	blot	for	IL‐1α after incubation of 
pro‐IL‐1α	with	active	caspases,	or	alone	(incubation	control;	IC).	(b)	IL‐1‐dependent	IL‐6	production	by	HeLa	cells	treated	with	reaction	
products	from	pro‐IL‐1α	incubated	±	active	caspases,	±neutralizing	IL‐1α antibody (α	pAb).	(c,	d)	Western	blot	(c)	and	bioactivity	(d)	of	IL‐1α 
after	incubation	±	caspase‐5,	±caspase	inhibitor	LEVD.	(e)	Multispecies	IL‐1α protein alignment showing conserved aspartic acid residue 
(arrow).	(f)	Western	blot	for	wild‐type	(WT)	or	mutant	D103A	pro‐IL‐1α	after	incubation	±	caspase‐5,	or	alone	(IC).	(g)	IL‐1‐dependent	IL‐6	
production	by	HeLa	cells	treated	with	reaction	products	from	WT	or	mutant	pro‐IL‐1α	incubated	±	caspase‐5,	±neutralizing	IL‐1α antibody 
(α	pAb).	(h)	Pictograph	showing	position	of	cleavage	sites	in	IL‐1α. Data represent mean ± SEM of n = 3 (g), n = 4 (b, d); p	=	**≤0.01,	***≤0.001,	
****≤0.0001;	ns	=	not	significant
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is constitutively expressed (Kajiwara et al., 2014), only caspase‐5 
(Figure	3a)	and	caspase‐11	(Figure	3b)	are	upregulated	by	LPS,	sug‐
gesting greater functional equivalence between caspase‐5 and cas‐
pase‐11.	Murine	 caspase‐1	 did	 not	 process	 (Figure	 3c)	 or	 activate	
(Figure	 3d)	 murine	 IL‐1α,	 while	 IL‐1β was cleaved and activated 
(Supporting	 information	 Figure	 S2a,b),	 confirming	 murine	 IL‐1α is 
not a caspase‐1 substrate. However, caspase‐11 cleaved murine 
pro‐IL‐1α at the conserved D106	 site	 (Figure	 3e),	 again	 increasing	
activity	 (Figure	 3f).	 Utilizing	 bone	 marrow‐derived	 macrophages	
(BMDMs)	 from	 WT,	 Casp11−/− and Casp1−/−/Casp11 transgenic 
(Tg)	mice	 showed	 total	 loss	 of	 cleaved	 IL‐1α	 (Figure	 3g)	 and	 IL‐1β 
(Figure	3h)	 secretion	by	Casp11−/− BMDMs, as expected (Kayagaki 
et	 al.,	 2011).	 Importantly,	 release	 of	 cleaved	 IL‐1α was reinstated 
in Casp1−/−/Casp11Tg	 BMDMs	 (Figure	 3i),	 suggesting	 IL‐1α only re‐
quires	 caspase‐11	 for	 cleavage	 and	 release	 after	 icLPS.	 The	 rea‐
son Casp1−/−/Casp11Tg	BMDMs	do	not	release	WT	levels	of	IL‐1α is 
thought to be due to incomplete complementation of endogenous 
Casp11 by the Casp11 transgene, as shown previously (Kayagaki et al., 
2011). Interestingly, Casp1−/−/Casp11Tg	BMDMs	did	not	release	IL‐1β 
(Figure	3j),	showing	IL‐1β requires both caspase‐1 and caspase‐11. To 
F I G U R E  2  Release	of	cleaved	IL‐1α	from	human	cells	requires	caspase‐5.	(a–d)	ELISA	data	showing	detection	of	recombinant	pro‐	
(p33),	calpain‐cleaved	(p17)	or	non‐calpain‐cleaved	(>p17)	IL‐1α	(a),	the	level	of	total	cleaved	IL‐1α	(b)	or	non‐calpain‐cleaved	IL‐1α (c) in the 
conditioned	media	of	HeLa	cells	transfected	with	WT	or	D103A	pro‐IL‐1α	and	treated	with	intracellular	LPS	(icLPS),	or	total	cleavage	of	WT	or	
D103A	pro‐IL‐1α	by	calpain	(d).	(e)	Western	blot	for	IL‐1α	in	HeLa	cells	transfected	with	WT	or	D103A	pro‐IL‐1α,	±icLPS	treatment.	(f,	g)	ELISA	
data	showing	level	of	non‐calpain‐cleaved	IL‐1α	in	the	conditioned	media	of	LPS	primed	human	monocyte‐derived	macrophages	(hMDMs)	
after	icLPS	(f)	or	ATP	(g)	treatment.	(h)	qPCR	data	showing	relative	gene	expression	in	hMDMs	after	transfection	of	control‐	or	CASP5‐
targeted	siRNA.	(i,	j)	ELISA	data	showing	level	of	total	cleaved	IL‐1α	(i)	or	non‐calpain‐cleaved	IL‐1α	(j)	in	the	conditioned	media	of	icLPS‐
treated hMDMs after transfection of control‐ or CASP5‐targeted	siRNA.	Data	represent	mean	±	SEM of n = 3 (b–d), n = 4 (h–j), or mean ± SD 
of n = 3 separate donors (f, g); p	=	*≤0.05,	**≤0.01,	***≤0.001;	ns	=	not	significant,	nd	=	not	detected
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determine	whether	caspase‐11	processing	of	pro‐IL‐1α	drives	IL‐1α 
release, as opposed to passive leakage after caspase‐11‐induced cell 
lysis,	we	expressed	 low	 levels	of	WT	or	D106A	murine	pro‐IL‐1α in 
immortalized	mBMDMs,	and	treated	with	icLPS.	Expression	of	WT	
IL‐1α	significantly	increased	release	of	cleaved	IL‐1α, while D106A	mu‐
tant expressing macrophages released the same amount of cleaved 
????????????????????????? ? ? ? ?? ? ????????????? ?????????????? ? ? ?? ? ????????????????? ??????????????
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IL‐1α	as	empty	vector‐transfected	cells	(Figure	3k).	Importantly,	no	
difference	in	viability	(Supporting	information	Figure	S3a,b)	or	IL‐1β 
release	 after	 icLPS	 was	 seen	 between	 groups	 (Figure	 3l),	 indicat‐
ing	effect	on	IL‐1α only. Together, these data show that caspase‐11 
cleavage	of	murine	IL‐1α at D106A	is	required	for	full	activity	and	re‐
lease	from	murine	macrophages,	while	 IL‐1β activation and release 
still require caspase‐1 and caspase‐11.
2.4 | Caspase‐5 is required for the IL‐1α‐dependent 
senescent‐associated secretory phenotype
The	 SASP	 directs	 clearance	 of	 senescent	 cells,	 but	 also	 drives	
chronic inflammation that can promote disease and unhealthy age‐
ing.	As	IL‐1α	drives	the	SASP,	we	investigated	whether	caspase‐5	is	
required	for	 IL‐1α	 release	during	senescence.	We	utilized	the	well‐
characterized	 tamoxifen‐inducible	 HRASG12V‐induced senescence 
of human IMR‐90 fibroblasts. Seven days after tamoxifen, cultures 
were	positive	for	senescence‐associated	beta‐galactosidase	(SAβG) 
(Figure	4a),	had	reduced	proliferation	(Figure	4b)	and	showed	senes‐
cence‐associated	heterochromatic	foci	(SAHF)	(Figure	4c).	Senescent	
cultures showed increased expression of CASP5 (Figure	 4d),	 cell	
surface	IL‐1α	(Figure	4e	and	Supporting	information	Figure	S4)	and	
total	cleaved	IL‐1α	in	the	conditioned	media	(Figure	4f),	compared	to	
growing cells. Importantly, similar low levels of death were found in 
growing	and	senescent	cultures	(Figure	4g),	excluding	passive	release	
of	IL‐1α	after	cell	 lysis.	Senescent	cells	released	the	common	SASP	
cytokines	IL‐6	(Figure	4h),	IL‐8	and	MCP‐1	(Supporting	information	
Figure	S5),	which	were	all	dependent	on	IL‐1α. Consistent with this, 
although	 pro‐IL‐1β was upregulated in senescent cells, negligible 
amounts were cleaved to the mature form and none was released 
from	the	cell	(Supporting	information	Figure	S6a,b).	siRNA‐mediated	
knockdown of CASP5 (Figure	4i)	led	to	significantly	less	cell	surface	
IL‐1α	(Figure	4j	and	Supporting	information	Figure	S4),	reduced	re‐
lease	of	 total	 (Figure	4k)	and	non‐calpain‐cleaved	 (Figure	4l)	 IL‐1α, 
and	a	subsequent	reduction	in	IL‐6,	IL‐8	and	MCP‐1	(Figure	4m–o).	
Caspase‐5	was	also	required	for	the	SASP	in	WI‐38	cells	(Supporting	
information	Figure	S7a–e).	With	either	cell	type,	CASP5 knockdown 
did	 not	 alter	 SAβG or proliferation levels (Supporting information 
Figure	S8a,b).	The	SASP	is	dependent	on	cGAS	sensing	of	cytosolic	
chromatin, which drives interferon signalling (Gluck et al., 2017; 
Yang,	Wang,	Ren,	Chen,	&	Chen,	2017).	As	CASP5 is interferon re‐
sponsive,	we	 tested	whether	 its	expression	was	cGAS‐dependent.	
cGAS knockdown	 resulted	 in	 reduced	 release	of	 IL‐1α	 and	 IL‐6,	 as	
expected, but also decreased CASP5 expression (Supporting infor‐
mation	Figure	S9a–d).	Together,	this	suggests	that	release	of	cleaved	
fully	active	IL‐1α	and	expression	of	the	subsequent	SASP	is	depend‐
ent	on	caspase‐5,	with	upstream	cGAS	potentially	controlling	CASP5 
expression.
2.5 | Caspase‐11 is required for immune 
surveillance of senescent cells in vivo
To	 investigate	whether	 caspase‐11	 is	 required	 for	 the	 SASP	 in	
vivo, we	used	a	mouse	liver	model	of	NRAS‐induced	senescence.	
Using hydrodynamic tail vein injection, we delivered Nras‐
IRES‐Casp11 shRNA	 or	 Nras‐IRES‐Control	 shRNA	 constructs	
that undergo transposon‐mediated stable integration into 
hepatocytes (Kang et al., 2011). This system was chosen as it de‐
creases caspase‐11 in only senescent cells, as opposed to all cells 
in Casp11−/− mice.	 Caspase‐11	 protein	was	 increased	 in	NRAS‐
positive	 cells	 after	 control	 shRNA	 treatment	 (Figure	 5a),	 with	
~97%	of	cells	co‐staining	for	NRAS	and	caspase‐11	(Figure	5b),	
while	 reduced	 caspase‐11	 protein	 (Figure	 5c,d)	 and	 transcript	
(Figure	 5e)	was	 seen	with	 the	Casp11‐targeted construct. This 
indicates	 that	 caspase‐11	 is	 upregulated	 during	NRAS‐induced	
hepatocyte senescence in vivo and that Casp11‐targeted	shRNA	
reduces	expression.	No	difference	in	the	number	of	NRAS‐posi‐
tive cells between control‐ or Casp11‐targeted	shRNA	was	seen	
at day 3, indicating equivalent integration and subsequent in‐
duction	of	senescence	by	NRAS	(Figure	5f,g).	However,	Casp11 
knockdown	caused	a	significant	accumulation	of	NRAS‐positive	
cells	 at	 days	 6	 and	 12	 (Figure	 5f,g),	 and	 a	 significant	 negative	
correlation existed between the level of caspase‐11 and num‐
ber	of	NRAS‐positive	cells	within	livers	(Supporting	information	
Figure	 S10),	 indicative	 of	 a	 reduction	 in	 SASP‐driven	 immune‐
mediated clearance. Consistent with this, the number of early 
infiltrating macrophages was decreased with Casp11 knockdown 
(Figure	 5h),	 along	with	 the	 number	 of	 immune	 cells	 clustering	
around	 NRAS‐positive	 cells	 (Supporting	 information	 Figure	
S11a,b).	Importantly,	the	number	of	Ki67/NRAS	double	positive	
cells	was	equivalent	between	groups	(Figure	5i),	eliminating	the	
possibility	that	accumulation	of	NRAS‐positive	cells	was	due	to	
Casp11 knockdown causing bypass of senescence. Together, this 
suggests	 that	 establishment	of	 the	 IL‐1α‐dependent	 SASP	 that	
drives immune surveillance and clearance is dependent on cas‐
pase‐11 in vivo.
F I G U R E  3  Release	of	cleaved	IL‐1α	from	murine	macrophages	requires	caspase‐11.	(a,	b)	qPCR	data	showing	changes	in	CASP4, CASP5 
(a) or Casp11 (b)	transcript	after	LPS	treatment	of	primary	human	(a)	or	mouse	(b)	macrophages.	(c)	Western	blot	for	IL‐1α after incubation 
of	murine	pro‐IL‐1α	with	murine	caspase‐1,	or	alone	(IC).	(d)	IL‐1‐dependent	IL‐6	production	by	murine	fibroblasts	treated	with	reaction	
products	from	murine	pro‐IL‐1α	incubated	±	murine	caspase‐1.	(e,	f)	Western	blot	of	murine	wild‐type	(WT)	or	D106A	pro‐IL‐1α (e) and 
bioactivity	of	murine	WT	pro‐IL‐1α	(f)	after	incubation	±	caspase‐11.	(g–l)	ELISA	data	showing	the	level	of	cleaved	IL‐1α	(g,	i,	k)	or	IL‐1β (h, j, l) 
detected	in	the	conditioned	media	of	mouse	bone	marrow‐derived	macrophages	(mBMDMs)	from	WT,	Casp11−/− (g, h) or Casp1−/−/Casp11Tg 
(i,	j)	mice,	or	immortalized	mBMDMs	transfected	with	empty,	WT	Il1a or	D106A	Il1a vectors	(k,	l),	followed	by	LPS	priming	and	then	
transfection	of	intracellular	LPS	(icLPS).	Data	represent	mean	±	SEM of n = 3 (a, b, f–l), n = 4 (d); p	=	**≤0.01,	***≤0.001,	****≤0.0001;	ns	=	not	
significant
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F I G U R E  4  Caspase‐5	is	required	for	the	IL‐1α‐dependent	SASP.	(a–c)	Representative	images	and	quantification	of	senescence‐associated	
beta‐galactosidase	(SAβG)	(a),	proliferation	by	BrdU	(b)	and	senescence‐associated	heterochromatic	foci	(SAHF)	(c)	in	growing	(Grow.)	and	
senescent	(Sen.)	IMR‐90	cells	(n.b.	b,	c	are	the	same	field	of	view).	(d–g)	Caspase‐5	expression	by	RNA‐Seq	(d),	cell	surface	IL‐1α by flow 
cytometry	(e),	cleaved	IL‐1α	in	the	conditioned	media	by	ELISA	(f)	and	level	of	cell	death	(g)	in	growing	and	senescent	IMR‐90	cells.	(h)	ELISA	
data	showing	the	level	of	IL‐6,	±neutralizing	IL‐1α antibody (α	pAb)	or	IL‐1RA	(RA)	in	the	conditioned	media	of	growing	and	senescent	IMR‐90	
cells.	(i)	qPCR	data	showing	relative	expression	of	CASP5 in senescent IMR‐90 cells after transfection of control‐ (Ctrl) or CASP5‐targeted 
siRNAs.	(j–o)	Cell	surface	IL‐1α	by	flow	cytometry	(j),	or	total	cleaved	IL‐1α	(k),	non‐calpain‐cleaved	IL‐1α	(l),	IL‐6	(m),	IL‐8	(n)	and	MCP‐1	(o)	by	
ELISA	in	the	conditioned	media	of	senescent	IMR‐90	cells	after	transfection	of	control‐	or	CASP5‐targeted	siRNA.	Data	represent	mean	±	SEM 
of n = 3, n = 4 (n, o), n = 6 (d); p	=	*≤0.05,	**≤0.01,	***≤0.001,	****≤0.0001;	ns	=	not	significant.	Scale	bars	=	100µm	(a),	15	µm	(b,	c)
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3  | DISCUSSION
Due	to	the	powerful,	pleiotropic	effects	of	IL‐1,	unprecedented	lev‐
els of control and feedback pathways are required to mount an im‐
mune response that resolves an insult without causing overt tissue 
damage.	For	example,	multiple	inflammasomes	have	evolved	to	dis‐
tinguish tissue damage, environmental pollutants, bacteria, viruses, 
fungi	and	protozoa.	IL‐1	also	drives	homeostatic	processes	such	as	
thermoregulation (Dinarello, 2009), regulatory B‐cell differentiation 
(Rosser et al., 2014), intestinal integrity (Jung et al., 2015), and the 
immune surveillance and clearance of senescence cells (Kang et al., 
2011).	However,	 how	 IL‐1α is cleaved, activated and released was 
unknown.
We	find	that	IL‐1α is directly cleaved by caspase‐5 and caspase‐11 
at a conserved site, leading to full cytokine activity. Expression of a 
caspase	site	mutant	IL‐1α or knockdown of CASP5 prevents release 
of	cleaved	IL‐1α	from	cells,	while	IL‐1α cleavage and release from mu‐
rine	macrophages	require	only	caspase‐11,	with	IL‐1β needing both 
caspase‐11	and	caspase‐1.	 Importantly,	 the	 IL‐1α‐dependent	SASP	
requires	caspase‐5	and	caspase‐11	 in	vitro	and	 in	vivo.	Thus,	 IL‐1α 
is a direct substrate of inflammatory caspases during noncanonical 
inflammasome activation and senescence.
The original Casp1−/− mice	 (Kuida	 et	 al.,	 1995;	 Li	 et	 al.,	 1995)	
showed	 loss	 of	 IL‐1β release from macrophages and during en‐
dotoxaemia.	Unexpected	 reduced	 levels	 of	 IL‐1α were also found, 
which	has	remained	a	puzzle	as	 IL‐1α is not a caspase‐1 substrate. 
F I G U R E  5   Caspase‐11 is required for immune surveillance of senescent cells in vivo. (a–d) Representative images (a, c) and quantification 
(b,	d)	of	caspase‐11	(green)	and	NRAS	(magenta)	staining	in	individual	liver	cells	6	days	after	hydrodynamic	tail	vein	injection	of	NRAS	with	
control‐ (a, b) or Casp11‐targeted	(c,	d)	shRNA	constructs.	White	arrows	indicate	NRAS	+	ve/caspase‐11	−ve	cells	(c).	(e)	qPCR	data	showing	
the level of Casp11 expression in livers 3 days after injection of constructs as indicated. (f, g) Representative images (f) and quantification 
(g)	of	NRAS	staining	(brown)	in	livers	after	the	time	and	injection	of	constructs	as	indicated.	(h)	Quantification	of	F4/80	staining	in	livers	
treated	as	indicated.	(i)	Quantification	of	number	of	Ki67/NRAS	double	+ve	cells	in	livers	6	days	after	injection	of	constructs.	Data	represent	
mean ± SEM of n = 5 (b, d, e, h, i), or as indicated (g); p	=	*≤0.05,	**≤0.01,	****≤0.0001;	ns	=	not	significant.	Scale	bars	=	50	μm	(a,	c),	300µm	(f)	
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However, Casp1−/− mice inherited a Casp11 inactivating passenger 
mutation from the 129/Sv background (Kayagaki et al., 2011). Our 
data	suggest	that	defective	release	of	cleaved	IL‐1α in Casp1−/− mice 
is likely due to the absence of caspase‐11. Indeed, serum levels of 
cleaved	 IL‐1α are undetectable during endotoxaemia (which acti‐
vates noncanonical inflammasomes via caspase‐11) in Casp11−/− 
and Casp1−/−/Casp11−/− mice, yet restored in the Casp1−/−/Casp11Tg 
(Kayagaki et al., 2011), supporting this concept. The primary role 
of	 caspase‐4/5	 and	 caspase‐11	 is	 thought	 to	 be	 LPS	 binding,	 and	
few substrates known. Gasdermin D is shown to be a key substrate 
for caspase‐11, caspase‐4/5 and indeed caspase‐1 (Kayagaki et al., 
2015;	Shi	et	al.,	2015).	We	now	report	IL‐1α as a direct substrate for 
caspase‐5 and caspase‐11.
Although	 independent	 publications	 show	 cleavage	 of	 IL‐1α 
greatly	increases	activity	(Afonina	et	al.,	2011;	Zheng	et	al.,	2013),	
others contest this (Kim et al., 2013). Kim et al purified	pro‐IL‐1α 
by	HPLC,	which	 typically	 denatures	 proteins	 due	 to	 the	 organic	
solvent mobile phase, and we find denatured and refolded pro‐
IL‐1α	has	more	activity	than	native	pro‐IL‐1α	(Zheng	et	al.,	2013).	
Regardless,	how	IL‐1α is released and if cleavage is required was 
unknown.	Gasdermin	D‐mediated	pore	formation	can	allow	IL‐1α 
to exit cells (Kayagaki et al., 2015; Shi et al., 2015). However, be‐
cause	all	 tested	IL‐1α	ELISA	kits	only	recognize	the	cleaved	form	
(K.	Wiggins,	M.	Humphry,	M.	Clarke	unpublished data), detection 
of	 IL‐1α within conditioned media represents both release and 
cleavage. Thus, active caspase‐5 or caspase‐11 could drive both 
the	direct	processing	of	IL‐1α and release via gasdermin D pores. 
In	addition,	pro‐IL‐1α	 is	bound	to	IL‐1R2	inside	many	cells,	which	
prevents	activation	by	calpain	(Burzynski	et	al.,	2015;	Zheng	et	al.,	
2013).	However,	caspase‐1	can	cleave	IL‐1R2	to	enable	IL‐1α acti‐
vation,	and	this	action	may	partly	control	canonical	 IL‐1α release 
(Zheng	et	 al.,	 2013).	 Interestingly,	 caspase‐5,	 but	 not	 caspase‐4,	
also	 cleaves	 IL‐1R2	 (Zheng	 et	 al.,	 2013).	 After	 canonical	 stimuli	
(e.g.,	 LPS/ATP),	 IL‐1α	 release	 is	 dependent	 on	 ASC	 and	 NLRP3	
(Kayagaki et al., 2011), while noncanonical stimuli only require 
caspase‐11	for	cleaved	IL‐1α	release	(Figure	3i	and	Kayagaki	et	al.,	
2011).	 This	 suggests	 that	 canonical	 IL‐1α release could proceed 
via	NLRP3	caspase‐1	activation	and	cleavage	of	 IL‐1R2,	followed	
by	calpain	cleavage	of	 IL‐1α, while noncanonical pathways could 
lead	 to	 IL‐1α	 release	after	direct	cleavage	of	 IL‐1R2	and	 IL‐1α by 
caspase‐5/11.
In	murine	 systems,	 caspase‐11	 binds	 LPS,	 increases	 caspase‐1	
cleavage	of	IL‐1β	(Wang	et	al.,	1998),	activates	gasdermin	D	(Kayagaki	
et al., 2015; Shi et al., 2015) and now also directly cleaves and ac‐
tivates	 IL‐1α. In humans, an ancestral gene duplication resulted in 
CASP4 and CASP5, with caspase‐4 suggested as the closer homo‐
logue of caspase‐11 (Shi et al., 2014). Both caspase‐4 and caspase‐5 
bind	LPS	and	target	gasdermin	D,	but	only	caspase‐5	can	comple‐
ment Casp11−/− cells (Shi et al., 2014), only CASP5 and Casp11 are 
upregulated	in	response	to	LPS	(Figure	3a,b),	and	only	caspase‐5/11	
can	cleave	IL‐1α,	suggesting	a	closer	functional	connection.	We	sug‐
gest caspase‐4 and caspase‐5 have most likely undergone subfunc‐
tionalization, with functionality of the ancestral Casp11‐like gene 
now distributed between both. However, if each performs nonre‐
dundant roles, and what these are, is still unknown.
Although	 IL‐1α induces sterile inflammation upon release from 
damaged	cells,	 it	also	drives	the	SASP,	but	 in	this	context	IL‐1α re‐
lease	or	 surface	presentation	occurs	without	cell	death	 (Figure	4g	
and	Gardner	et	al.,	2015).	This	excludes	the	usual	notion	that	IL‐1α 
is	passively	released	(Kayagaki	et	al.,	2011).	IL‐1α expression during 
the	SASP	is	controlled	in	part	by	ATM/ATR	liberation	of	GATA4	from	
p62‐directed autophagy (Kang et al., 2015) and/or an mTORC1‐de‐
pendent	pathway	(Laberge	et	al.,	2015).	Also,	redox	balance	and	Ca2+	
levels	 may	 enhance	 calpain	 processing	 of	 IL‐1α in senescent cells 
(McCarthy,	Clark,	Bartling,	 Trebak,	&	Melendez,	 2013).	 Thus,	 how	
active	 IL‐1α is released without cell death during senescence was 
unknown. Here, we report increased CASP5 or Casp11 expression in 
senescent	cells	and	a	loss	of	cell	surface	and	released	IL‐1α without 
caspase‐5,	leading	to	inhibition	of	the	SASP.	Interestingly,	the	SASP	
is	not	dependent	on	IL‐1β (Gardner et al., 2015; Orjalo et al., 2009), 
implying	 cleaved	 IL‐1α	 release	 occurs	 separately	 from	 IL‐1β (e.g., 
without	caspase‐1/NLRP3/ASC),	in	contrast	to	other	studies	(Acosta	
et	 al.,	 2013).	 Indeed,	 IL‐1β	 release	 after	 icLPS	 requires	 caspase‐1	
and	caspase‐11,	while	 IL‐1α	only	requires	caspase‐11	 (Figure	3g–j).	
Together,	this	suggests	that	cleavage	of	IL‐1α by caspase‐5/11 during 
senescence	 leads	 to	 release	 of	 active	 IL‐1α only, which drives the 
SASP.	 Interestingly,	CASP5 mutations are associated with cancers 
(Offman et al., 2005), while CASP1 and CASP4 mutations are not 
(Soung et al., 2008), suggesting a caspase‐5‐specific protective role 
against	 tumorigenesis	 that	 is	 in	 keeping	 with	 SASP‐driven	 senes‐
cence surveillance.
In	conclusion,	we	show	that	IL‐1α is a direct substrate of the non‐
canonical inflammatory caspase‐5 and caspase‐11, with cleavage in‐
creasing cytokine activity and release. Conservation of the cleavage 
site	 between	 species	 implies	 that	 activation	of	 IL‐1α by caspase‐5 
or	caspase‐11	 is	 important.	 Indeed,	cleavage	of	 IL‐1α by caspase‐5 
or	 caspase‐11	 is	 essential	 for	 the	 SASP.	 Thus,	 directly	 targeting	
caspase‐5 may reduce inflammation and limit the deleterious effects 
of senescent cells that accumulate during disease and ageing.
4  | MATERIAL S AND METHODS
All	material	from	Sigma‐Aldrich	unless	otherwise	stated.
4.1 | Cell culture
HeLa	 cells	 (ECACC)	 and	 primary	mouse	 fibroblasts	were	 cultured	
in	DMEM	with	 penicillin,	 streptomycin,	 L‐glutamine	 and	 10%	 FCS	
and	 passaged	 at	 80%	 confluency.	 IMR‐90	 and	WI‐38	 cells	 (ATCC)	
were cultured in phenol red‐free DMEM supplemented with penicil‐
lin,	streptomycin	and	10%	FCS.	Bone	marrow‐derived	macrophages	
(BMDMs) from wild‐type, Casp11−/− or Casp1−/−Casp11Tg (Kayagaki 
et	al.,	2011)	mice	(C57BL6/J	background,	8–12	weeks	old)	were	dif‐
ferentiated	in	RPMI	1640	with	penicillin,	streptomycin,	L‐glutamine,	
10%	 FCS	 and	 15%	 L929	 conditioned	 media,	 while	 immortalized	
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BMDMs	used	the	same	media,	but	without	L929.	Human	monocyte‐
derived macrophages were isolated from whole blood (obtained 
with	 informed	 consent;	 NRES	 Committee,	 East	 of	 England)	 with	
Percoll	 gradients	 and	 differentiated	 in	 Iscove's	with	 streptomycin,	
L‐glutamine	 and	 10%	 autologous	 serum.	 IMR‐90	 and	WI‐38	 cells	
were transduced with retrovirus carrying ER:HRASG12V	 in	pLNCX2	
(Clontech), as previously described (Young et al., 2009), and senes‐
cence	 induced	 with	 4‐hydroxytamoxifen	 (100	nM).	 All	 cells	 were	
checked	 for	mycoplasma	 contamination	 (MycoAlert,	 Lonza).	 HeLa	
cells	were	transfected	with	pcDNA3	(Invitrogen)	using	FuGENE	HD	
(Promega),	while	immortalized	mBMDMs	used	Amaxa	nucleofection	
(Lonza),	before	incubation	(48h,	37°C).	Knockdown	in	primary	mac‐
rophages was performed with 10 pmol of nontargeting or CASP5‐
targeting	 siGENOME	 siRNA	 pool	 (Dharmacon),	 while	 knockdown	
in	 IMR‐90	and	WI‐38	cells	was	performed	with	10	pmol	of	pooled	
or individual CASP5‐ or cGAS‐targeting	 siGENOME	 siRNAs,	 using	
Lipofectamine	 RNAiMAX	 (Invitrogen)	 as	 per	 the	 manufacturer's	
instructions.	Cell	viability	was	assessed	by	LDH	release	(Pierce),	or	
crystal violet staining as previously described (Gardner et al., 2015).
4.2 | IL‐1 Bioassays and inflammasome activation
HeLa	 cells	 or	 mouse	 fibroblasts	 were	 plated	 (10,000	 cells/well,	
48‐well	 plate)	 and	 incubated	 (16	hr,	 37°C).	 Media	 was	 refreshed	
and	 cells	 incubated	 (6	hr,	 37°C)	±	cleavage	 assay	 products	 (1.5	µl).	
Specific	 IL‐1	activity	was	 inferred	by	 the	effect	of	neutralizing	an‐
tibodies	(2	µg/ml;	same	as	for	Westerns),	on	IL‐6	production.	Every	
experiment contained a media only negative control and a recombi‐
nant	 IL‐1	 (10	ng/ml;	PeproTech)	positive	control.	For	noncanonical,	
cells	were	primed	with	ultrapure	LPS	 (1	µg/ml,	4	hr;	 InvivoGen)	 in	
full	media,	transfected	with	ultrapure	LPS	(5	µg/ml)	using	FuGENE	
HD	(2.5	µl/ml;	Promega)	and	incubated	in	Opti‐MEM	(37˚C,	18	hr).	
For	canonical,	cells	were	primed	with	ultrapure	LPS	(1	µg/ml,	4	hr)	in	
full	media,	treated	with	ATP	(5	mM,	pH7;	InvivoGen)	and	incubated	
in	Opti‐MEM	(37˚C,	18	hr).
4.3 | Recombinant protein expression, 
purification and cleavage
Pro‐IL‐1α/β	or	pro‐caspase‐5	cDNAs	were	cloned	into	pGEX‐4T‐3	
(GE)	or	pcDNA3	 (Invitrogen),	with	mutations	 introduced	by	 site‐
directed	 mutagenesis.	 For	 bacterial	 expression,	 IPTG‐induced	
Rosetta	 cultures	were	 lysed	 (PBS	 1×;	DTT	 1	mM;	 EDTA	 10	mM;	
benzonase	30	U/ml;	 lysozyme	55	kU/g	 (both	Novagen);	 protease	
inhibitor cocktail) with sonication, and clarified by centrifuga‐
tion	 (5,525	g,	1	hr,	4°C).	Filtered	 supernatants	were	 loaded	onto	
a	 GSTrap	 column	 (GE),	 washed	 (PBS;	 DTT	 1	mM;	 EDTA	 1	mM)	
and	eluted	(Tris	50	mM;	NaCl	100	mM;	DTT	1	mM;	reduced	l‐glu‐
tathione	50	mM;	 adjusted	 to	pH	8)	 using	 an	ÅKTA	FPLC	 system	
(GE). Eluted protein was dialysed overnight (Tris 10 mM, pH8; 
NaCl	50	mM)	and	stored	 in	glycerol	 (10%)	at	−80°C.	 IL‐1	protein	
concentration	 was	 normalized	 by	 SDS‐PAGE,	 Coomassie	 stain‐
ing	 (G‐250;	Bio‐Rad)	 and	quantitative	 imaging	 (Odyssey,	 Li‐Cor).	
Recombinant	 IL‐1	 (4	µg/ml)	 was	 incubated	 (1	hr,	 37°C)	 with	 ac‐
tive caspase (100 U or 10 U; all Enzo) in reaction buffer (human—
HEPES	50	mM,	pH	7.4;	NaCl	100	mM;	CHAPS	0.1%;	EDTA	1	mM;	
glycerol	10%;	DTT	10	mM)	(mouse—MES	100	mM,	pH	6.5;	CHAPS	
0.1%;	 PEG	 10%;	 DTT	 10	mM).	 Where	 indicated,	 LEVD‐FMK	
(330	µM;	Enzo)	was	added.	Recombinant	IL‐1	(4	µg/ml)	was	incu‐
bated (1 hr, RT) with active calpain (100 U; Calbiochem) in reaction 
buffer	(NaCl	100	mM;	CaCl2	2	mM;	DTT	1	mM).
4.4 | Induction of mouse hepatocyte senescence 
in vivo
Mice were handled and kept under pathogen‐free conditions in ac‐
cordance with UK law and institutional guidelines at the University 
of Cambridge and CRUK Cambridge Institute. Transposon‐mediated 
gene transfer by hydrodynamic tail vein injection was as previously 
described (Dauch et al., 2016; Kang et al., 2011). Briefly, short‐hair‐
pin oligomers targeting Casp11 (5’‐TACCATCTATCAGATATTCAA‐3’)	
were	 cloned	 into	 MSCV‐miR30‐puro	 before	 subcloning	 into	
pCaNIG‐miR30	 (from	 Lars	 Zender	 (Dauch	 et	 al.,	 2016)).	 Vectors	
were	prepared	using	 the	EndoFree	MaxiPrep	Kit	 (Qiagen).	 Female	
C57BL/6	mice	(Charles	River)	were	injected	via	the	lateral	tail	vein	
with	pCaNIG‐miR30	(20	µg)	and	SB13	transposase	vector	(5	µg)	in	
PBS	at	a	volume	equivalent	to	10%	of	body	weight	in	<10	s,	and	liv‐
ers harvested at the times indicated.
4.5 | Western blotting and cytokine detection
Western	blotting	was	performed	as	previously	described.	Blocked	
PVDF	 membranes	 (Bio‐Rad)	 were	 incubated	 (16	hr,	 4°C)	 with	
anti‐human	 IL‐1α	 (500‐P21A,	 PeproTech;	 1:500),	 anti‐mouse	 IL‐1α 
(AF‐400NA,	 R&D;	 1:500),	 anti‐human	 IL‐1β	 (AF‐201‐NA,	 R&D;	
1:500)	 or	 anti‐mouse	 IL‐1β	 (500‐P51,	 PeproTech;	 1:500).	 Binding	
was	detected	with:	anti‐rabbit	HRP	(NA934V,	GE)	or	anti‐goat	HRP	
(805‐035‐180,	 Jackson	 ImmunoResearch)	 (both	 1:2000),	 ECL	 rea‐
gents	 (GE)	 and	 apposition	 to	 X‐ray	 film	 (Fujifilm).	 Cytokines	were	
measured	using	human	or	mouse	IL‐1α,	 IL‐1β,	 IL‐6,	 IL‐8	and	MCP‐1	
bead	 immunoassays	 (Life	Technologies),	 as	per	 the	manufacturer's	
instructions,	 and	 assayed	with	 a	 flow	 cytometer	 (Accuri	 C6).	 The	
antibody binding to the region between the calpain and caspase‐5 
cleavage	 site	 in	 IL‐1α was generated by immunizing rabbits with a 
KLH‐conjugated	peptide,	followed	by	affinity	purification	and	bioti‐
nylation (Innovagen). This was then used as the detection reagent in 
a	standard	sandwich	ELISA	using	a	goat	anti‐human	IL‐1α antibody 
(R&D)	as	capture.
4.6 | Gene expression analysis
RNA	was	 isolated	 (RNeasy,	Qiagen)	 and	converted	 to	 cDNA	using	
AMV	 reverse	 transcriptase	 (Promega).	 qPCR	used	TaqMan	probes	
with	 AmpliTaq	 Gold	 (Life	 Technologies)	 in	 a	 Rotor‐Gene	 thermo‐
cycler (Corbett). Gene expression was evaluated using the 2−ΔΔCT 
method	using	GUSB	as	a	reference	gene.	qPCR	data	are	displayed	as	
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2−ΔΔCT, but statistical analysis was performed on the untransformed 
ΔΔCT	values.	RNA‐Seq	data	were	from	GEO	GSE72404.
4.7 | Assessment of Cell Surface IL‐1α
Cells	were	detached	(Accutase),	fixed	(2%	formaldehyde;	5	min,	RT),	
washed	(BSA,	0.5%;	NaN3,	0.05%;	in	PBS),	Fc	blocked	(10	min,	RT;	
BioLegend;	 1:100),	 before	 incubation	 (30	min,	 RT)	with	 anti‐IL‐1α‐
FITC	(FAB200F,	R&D;	1:20)	or	 isotype	control‐FITC	(IC002F,	R&D;	
1:20),	before	washing	and	analysis	by	flow	cytometry	(Accuri	C6).
4.8 | SAβG, BrdU and SAHF staining
For	SAβG	staining,	 cells	were	washed	 (PBS),	 fixed	 (0.5%	glutaral‐
dehyde,	 10	min,	 RT),	 washed	 (MgCl2	 1	mM/PBS)	 and	 stained	 in	
X‐gal	 solution	 (X‐gal,	 1	mg/ml;	 K3Fe[CN]6,	 0.12	mM;	K4Fe[CN]6,	
0.12	mM;	MgCl2,	1	mM;	in	PBS,	pH	6.0)	overnight	(37°C).	For	BrdU	
and	SAHF	with	5‐bromo‐2’‐deoxyuridine	(BrdU;	100	µg/ml),	fixed	
(4%	formaldehyde;	15	min,	RT),	permeabilized	(0.2%	Triton	X‐100/
PBS),	 blocked	 (0.5%	 goat	 serum)	 and	 incubated	 with	 anti‐BrdU	
(555,627,	 BD;	 1:500),	 washed	 (Tween	 0.05%/PBS;	 5	min)	 and	 in‐
cubated	(1	hr)	with	goat	anti‐mouse	Alexa	488	(A‐11034,	Thermo	
Fisher;	 1:500).	 Cells	 were	 mounted	 in	 VECTASHIELD	 (Vector	
Laboratories)	with	DAPI	(1	µg/ml)	and	imaged	with	a	TCS	SP8	mi‐
croscope	(Leica).
4.9 | Immunofluorescence and 
Immunohistochemistry
After	 processing,	 paraffin	 sections	 were	 cleared	 before	 antigen	
retrieval with sodium citrate (10 mM; pH 6), blocking with M.O.M. 
(Vector	 Laboratories)	 and	donkey	 serum	 (0.5%,	1	hr),	 and	 then	 in‐
cubated	 (4°C,	 16	hr)	 with	 antibodies	 to	 anti‐NRAS	 (sc‐31,	 Santa	
Cruz;	1:250),	 anti‐caspase‐11	 (MAB86481,	R&D;	1:50),	 anti‐F4/80	
(MCA497,	 Serotec;	 1:100)	 and	 anti‐Ki67	 (GTX16667,	 GeneTex;	
1:500).	After	washing	(Tween	0.05%/PBS;	5	min),	primary	antibodies	
were	visualized	with	donkey	anti‐rat	Alexa	488	(ab150153,	Abcam),	
donkey	anti‐mouse	Alexa	647	(A31571,	Invitrogen),	donkey	anti‐rab‐
bit	Alexa	 555	 (A31572,	 Invitrogen;	 all	 1:250)	 or	 the	 EnVision	+	kit	
(K500711‐2,	Agilent	Technologies).
Autofluorescence	was	reduced	by	 incubation	 (10	min,	RT)	with	
Sudan	Black	(0.1%	in	70%	EtOH)	before	mounting	in	VECTASHIELD	
(Vector	 Laboratories)	with	DAPI	 (1	µg/ml),	 or	 counterstained	with	
haematoxylin.	 Slides	 were	 imaged	 or	 scanned	 on	 an	 Aperio	 AT2	
(Leica).	 Images	 were	 analysed	 with	 HALO	 (Indica	 Labs)	 and	 the	
Cytonuclear v1.4 algorithm.
4.10 | Statistical Analysis
All	 statistical	 analyses	were	 carried	out	using	Prism	7	 (GraphPad).	
Data were analysed by unpaired t	test	(two‐tailed),	one‐way	ANOVA	
with	Dunnett's	post	hoc	or	one‐way	ANOVA	with	Tukey's	post	hoc.	
n = individual biological replicate performed in duplicate. The in vitro 
experiments typically required sample sizes of n = 3–4 to provide 
adequate power, and produced data that were normally distributed.
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